BioSpace News Archive

Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial.

Ultragenyx Pharmaceutical Inc. reported the grant of 36,300 restricted stock units of the company’s common stock to 21 newly hired non-executive officers of the company.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814).

Santen Pharmaceutical Co., Ltd. announced that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”) is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company’s Board of Directors (the “Board”).

AIM ImmunoTech Inc. issued a notice that the Company has learned that unknown person and/or organization are claiming to represent AIM ImmunoTech Europe and are using the Company’s name without authorization.

Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the pricing of a global offering of ordinary shares, which may be represented by American Depository Shares.

Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS) today announced the pricing of an upsized underwritten public offering of 16,774,193 shares of its common stock at a price to the public of $7.75 per share.